Corbus Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Updates
November 10, 2020 07:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Company intends to shorten fully-enrolled Phase 3 dermatomyositis trial to 28 weeks from 52 weeks following recent developments in competitive landscape; data now expected as early as the second...